Everolimus acts directly on mTOR and is approved for lung, gastrointestinal, neuroendocrine tumors, and advanced renal carcinoma while selumetinib directly inhibits ERK, and its application is approved for neurofibromas [36,37]. The gene discussed is MTOR; the disease is neuroendocrine neoplasm.